Since the first CD19-CAR T cell therapy for patients with acute lymphoblastic leukemia (ALL) was approved by the FDA in 2017, investigators have concentrated on extending the therapeutic effects of CAR T cells not only for B cell malignancies but also for several other cancers, including solid tumors. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.